Research Analyst at TD Cowen
Greg Weasner is an Equity Research Analyst at TD Cowen specializing in biotechnology and healthcare sector coverage, with a particular focus on companies such as Aadi Bioscience. His recent research includes direct participation in earnings call discussions with senior management, demonstrating active coverage and sector expertise. Weasner began his career in equity research in the early 2020s and has built a record of thorough analysis, though publicly available performance metrics such as TipRanks rankings and return data are limited. He maintains industry-recognized credentials, including relevant FINRA securities licenses required for US sell-side analysts.
Asked about the focus on specific tumor types versus a pan-tumor approach for future trials, related FDA guidance, and the venue for the upcoming data release.
The company confirmed PRECISION1 is strictly tumor-agnostic and designed per FDA expectations for such trials, with separate studies for specific indications like EEC and NET. The upcoming data will be released via a company presentation.